Note to editor

ESC press office
Phone number: +33(0)489 872 075

Email: press@escardio.org

Follow me on X: @ESCardioNews

Funding: AFFECT-EU is funded by the European Union’s Horizon 2020 research and innovation program Under Grant Agreement No. 847770.

References and notes

¹Hindrix G, Popala T, Dagles N, other. His 2020 ESC guidelines for the diagnosis and management of atrial fibrillation were developed in collaboration with the European Association for Cardiothoracic Surgery (EACTS). euro heart j. 2020;42:373-498.

²Kryte BP, Kunst A, Benjamin EJ, other. Projection of the number of patients with atrial fibrillation in the European Union from 2000 to 2060. euro heart j. 2013;34(35):2746-2751.

³Healy JS, Connolly SJ, Gold MR; other. Subclinical atrial fibrillation and stroke risk. N English J Medicine 2012;366(2):120-129.

^FourSamor A, Masin M, Gellner R, other. Unknown prevalence of atrial fibrillation in patients with risk factors. Europe. 2013;15(5):657-662.

^FiveMcIntyre WF, Diederiksen SZ, Friedman B, other. Screening for atrial fibrillation to prevent stroke: a meta-analysis. euro heart j open. 2022;2(4):oeac044.

⁶Engler D, Hanson CL, Destege L, other. Feasible approaches and implementation challenges to atrial fibrillation screening: A qualitative study of stakeholder views in 11 European countries. BMJ Open. 2022;12(6):e059156.

⁷Vermunicht P, Grech M, DeHaro JC, other. General practitioners’ perceptions of opportunistic single-point screening for atrial fibrillation: a quantitative European survey. front cardiovascular medicine. 2023;10:1112561.

⁸Moses B, Gehrhod B, Linneberg A, other. Atrial fibrillation incidence, attributable risk factors, and risk of stroke and death by age: Results from the MORGAM consortium. open heart. 2021;8(2):e001624.

⁹Cammen S, Sengeri D, Gehrhod B, other. Risk factors for myocardial infarction and atrial fibrillation, subsequent disease development, and impact on prognosis. J. Am Heart Assoc. 2022;11(7):e024299.

^TenToprak B, Brandt S, Brederecke J, other. Using regression and modern machine learning techniques, we investigate the graded utility of circulating biomarkers for reliable risk prediction of developing atrial fibrillation in a European cohort. Europe. 2023;25(3):812-819.

¹¹Palà E, Bustamante A, Clúa-Espuny JL, other. Blood biomarkers and devices for atrial fibrillation screening: Lessons learned from the AFRICAT (Atrial Fibrillation Research in Catalonia) study. PLoS One. 2022;17(8):e0273571.

¹²Xing LY, Diederiksen SZ, Heuberg S, other. Efficacy of atrial fibrillation screening with N-terminal pro-B-type natriuretic peptide: secondary analysis of the randomized LOOP study. Circulation. 2023;147(24):1788-1797.

¹³Xing LY, Diederiksen SZ, Heuberg S, other. Effectiveness of screening for atrial fibrillation using systolic blood pressure and long-term continuous monitoring (LOOP substudy). high blood pressure. 2022;79(9):2081-2090.

¹⁴Alkouri M, Alqahtani F, Aljohani S, other. Burden of atrial fibrillation-associated ischemic stroke in the United States. JACC Clin electrophysiological test. 2018;4(5):618-625.

About the European Society of Cardiology

ESC brings together medical professionals from more than 150 countries working to advance cardiovascular medicine and help people live longer, healthier lives.